These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 29429963)

  • 1. Impact of comorbidity on tolerability and survival following curative intent intensity modulated radiotherapy in older patients with nasopharyngeal cancer.
    Sommat K; Yit NLF; Wang F; Lim JHC
    J Geriatr Oncol; 2018 Jul; 9(4):352-358. PubMed ID: 29429963
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Characteristics and Survival Outcomes in Patients Aged 70 Years and Older with Nasopharyngeal Carcinoma in the Intensity-Modulated Radiotherapy Era.
    Jin YN; Zhang WJ; Cai XY; Li MS; Lawrence WR; Wang SY; Mai DM; Du YY; Luo DH; Mo HY
    Cancer Res Treat; 2019 Jan; 51(1):34-42. PubMed ID: 29409313
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intensity-modulated radiotherapy for elderly patients with nasopharyngeal carcinoma.
    Cao C; Hu Q; Chen X
    Head Neck; 2018 Mar; 40(3):590-595. PubMed ID: 29155480
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment outcomes and late toxicities of 869 patients with nasopharyngeal carcinoma treated with definitive intensity modulated radiation therapy: new insight into the value of total dose of cisplatin and radiation boost.
    Ou X; Zhou X; Shi Q; Xing X; Yang Y; Xu T; Shen C; Wang X; He X; Kong L; Ying H; Hu C
    Oncotarget; 2015 Nov; 6(35):38381-97. PubMed ID: 26485757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcomes of intensity-modulated radiotherapy for 868 patients with nasopharyngeal carcinoma: an analysis of survival and treatment toxicities.
    Sun X; Su S; Chen C; Han F; Zhao C; Xiao W; Deng X; Huang S; Lin C; Lu T
    Radiother Oncol; 2014 Mar; 110(3):398-403. PubMed ID: 24231245
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term Survivals, Toxicities and the Role of Chemotherapy in Early-Stage Nasopharyngeal Carcinoma Patients Treated with Intensity-Modulated Radiation Therapy: A Retrospective Study with 15-Year Follow-up.
    Wang L; Miao J; Huang H; Chen B; Xiao X; Zhu M; Liang Y; Xiao W; Huang S; Peng Y; Deng X; Lv X; Xia W; Xiang Y; Guo X; Han F; Zhao C
    Cancer Res Treat; 2022 Jan; 54(1):118-129. PubMed ID: 34098625
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of intensity-modulated radiotherapy alone versus intensity-modulated radiotherapy plus chemotherapy for treatment of intermediate-risk nasopharyngeal carcinoma.
    Aftab O; Liao S; Zhang R; Tang N; Luo M; Zhang B; Shahi S; Rai R; Ali J; Jiang W
    Radiat Oncol; 2020 Mar; 15(1):66. PubMed ID: 32178698
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of the seventh and eighth editions of the UICC/AJCC staging system for nasopharyngeal carcinoma: analysis of 1317 patients treated with intensity-modulated radiotherapy at two centers.
    Yang XL; Wang Y; Liang SB; He SS; Chen DM; Chen HY; Lu LX; Chen Y
    BMC Cancer; 2018 May; 18(1):606. PubMed ID: 29843648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival impact of radiotherapy interruption in nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A big-data intelligence platform-based analysis.
    Yao JJ; Zhang F; Gao TS; Zhang WJ; Lawrence WR; Zhu BT; Zhou GQ; Ma J; Wang SY; Sun Y
    Radiother Oncol; 2019 Mar; 132():178-187. PubMed ID: 30448002
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significance of chemotherapy for older patients with nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A propensity score matching analysis.
    Chen J; Ding J; Xu Y; Hong H; Lin X; Xu M; Yan L; Xu T; Fei Z; Chen C
    J Geriatr Oncol; 2023 Nov; 14(8):101648. PubMed ID: 37897887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Competing risk nomograms for nasopharyngeal carcinoma in the intensity-modulated radiotherapy era: A big-data, intelligence platform-based analysis.
    Huang XD; Zhou GQ; Lv JW; Zhou HQ; Zhong CW; Wu CF; Zheng ZQ; He XJ; Peng L; Ma J; Sun Y
    Radiother Oncol; 2018 Nov; 129(2):389-395. PubMed ID: 30270098
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implication of comorbidity on the initiation of chemotherapy and survival outcomes in patients with locoregionally advanced nasopharyngeal carcinoma.
    Guo R; Mao YP; Chen L; Tang LL; Zhou GQ; Liu LZ; Tian L; Zeng MS; Jia WH; Shao JY; Lin AH; Ma J
    Oncotarget; 2017 Feb; 8(6):10594-10601. PubMed ID: 27070084
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction chemotherapy plus IMRT alone versus induction chemotherapy plus IMRT-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study.
    Wei Z; Zhang Z; Luo J; Li N; Peng X
    J Cancer Res Clin Oncol; 2019 Jul; 145(7):1857-1864. PubMed ID: 31062162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival without concurrent chemotherapy for locoregionally advanced nasopharyngeal carcinoma treated with induction chemotherapy plus intensity-modulated radiotherapy: Single-center experience from an endemic area.
    Fangzheng W; Chuner J; Haiyan Q; Quanquan S; Zhimin Y; Tongxin L; Jiping L; Peng W; Kaiyuan S; Zhenfu F; Yangming J
    Medicine (Baltimore); 2019 Dec; 98(51):e18484. PubMed ID: 31861031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment outcomes of nasopharyngeal carcinoma in modern era after intensity modulated radiotherapy (IMRT) in Hong Kong: A report of 3328 patients (HKNPCSG 1301 study).
    Au KH; Ngan RKC; Ng AWY; Poon DMC; Ng WT; Yuen KT; Lee VHF; Tung SY; Chan ATC; Sze HCK; Cheng ACK; Lee AWM; Kwong DLW; Tam AHP
    Oral Oncol; 2018 Feb; 77():16-21. PubMed ID: 29362121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Multicentre UK Study of Outcomes of Nasopharyngeal Carcinoma Treated With Intensity-Modulated Radiotherapy ± Chemotherapy.
    Slevin F; Pan S; Mistry H; Sen M; Foran B; Slevin N; Dixon L; Thomson D; Prestwich R
    Clin Oncol (R Coll Radiol); 2020 Apr; 32(4):238-249. PubMed ID: 31813661
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvage treatment using carbon ion radiation in patients with locoregionally recurrent nasopharyngeal carcinoma: Initial results.
    Hu J; Bao C; Gao J; Guan X; Hu W; Yang J; Hu C; Kong L; Lu JJ
    Cancer; 2018 Jun; 124(11):2427-2437. PubMed ID: 29579324
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognosis of nasopharyngeal carcinoma with insufficient radical dose to the primary site in the intensity-modulated radiotherapy era.
    Lu T; Xie X; Guo Q; Zhan S; Lin C; Lin S; Zhang Y; Zong J; Pan J
    Head Neck; 2019 Oct; 41(10):3516-3524. PubMed ID: 31313419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical outcomes of carbon-ion radiotherapy for patients with locoregionally recurrent nasopharyngeal carcinoma.
    Hu J; Huang Q; Gao J; Guan X; Hu W; Yang J; Qiu X; Chen M; Kong L; Lu JJ
    Cancer; 2020 Dec; 126(23):5173-5183. PubMed ID: 32931035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Stage-dependent conditional survival and failure hazard of non-metastatic nasopharyngeal carcinoma after intensity-modulated radiation therapy: Clinical implications for treatment strategies and surveillance.
    Wang J; Huang X; Sun S; Wang K; Qu Y; Chen X; Wu R; Zhang Y; Liu Q; Zhang J; Luo J; Xiao J; Gao L; Xu G; Hu C; Li YX; Yi J
    Cancer Med; 2021 Jun; 10(11):3613-3621. PubMed ID: 33960136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.